Illumina at a fresh 52-week high, Bernstein SocGen resumes coverage on the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 09:30.

Illumina Inc. (US4523271090) is back on the radar of Wall Street research. The NASDAQ-listed sequencing specialist has just seen Bernstein SocGen resume coverage with a Market Perform rating and a price target of 185 US dollars, according to an analyst note reported by Investing.com.

What Bernstein SocGen highlights

Bernstein SocGen’s team places the new 185 dollar target against a share price that recently traded at about 160.22 dollars, a level described as sitting at Illumina’s 52-week high on NASDAQ. The rating of Market Perform signals neither an outright bullish nor a strongly cautious stance.

The analysts point to a difficult past 18 months that included a "China reset" after Beijing placed Illumina on its Unreliable Entities List in early 2025, triggering import restrictions on sequencer instruments and weighing on estimates through spring and summer. Since then, a recovery in demand has been supported by the company’s NovaSeq X high-throughput sequencer and growing clinical applications.

Guidance, recent results and other analyst views

Beyond the new coverage, Bernstein SocGen notes that Illumina’s early-2026 stock decline was linked to fiscal year 2026 guidance calling for 4 to 6 percent reported revenue growth, 2 to 4 percent rest-of-world organic growth and earnings per share of 5.05 to 5.20 dollars. Those figures framed expectations for a still-growing but more measured trajectory after earlier volatility.

The narrative shifted somewhat with the first quarter of 2026, where Illumina reported more than 80 NovaSeq X placements, clearly ahead of the previously expected 50 to 60 systems per quarter and described as above expectations in the analyst commentary. Guggenheim has also weighed in on the stock, lifting its price target to 180 dollars while reiterating a Buy rating in a separate update cited alongside Bernstein SocGen’s note.

The products behind the stock

Illumina generates most of its revenue from sequencing systems and consumables, with the NovaSeq X platform currently at the center of high-throughput applications in research and clinical genomics. The company also offers sequencing reagents, sample preparation kits and informatics solutions built around its DRAGEN secondary analysis pipeline to support oncology, rare disease and population genomics projects.

Where the shares trade today

Illumina shares (US4523271090) most recently closed on NASDAQ at 176.55 US dollars on 2026-06-26, 16:00 Eastern Time, according to MarketBeat price data.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.